ResMed Inc. (ASX:RMD)
| Market Cap | 55.05B |
| Revenue (ttm) | 7.95B |
| Net Income (ttm) | 2.17B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 25.32 |
| Forward PE | 22.36 |
| Dividend | 0.34 (0.90%) |
| Ex-Dividend Date | Nov 12, 2025 |
| Volume | 911,278 |
| Average Volume | 1,181,520 |
| Open | 37.80 |
| Previous Close | 38.41 |
| Day's Range | 37.51 - 37.88 |
| 52-Week Range | 32.04 - 45.25 |
| Beta | 0.87 |
| RSI | 41.27 |
| Earnings Date | Jan 22, 2026 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial numbers in USD Financial StatementsNews
RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort
Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
Top 50 High-Quality Dividend Growth Stocks For December 2025
I track a custom universe of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities based on valuation and forward return potential. 28 of these stocks currentl...
Resmed Gets FDA Clearance For Personalized Therapy Comfort Settings; To Be Marketed As Smart Comfort
(RTTNews) - Resmed (RMD, RMD.AX), Monday announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed as Smart Comfort.
Resmed (RMD) Achieves FDA Clearance for Smart Comfort Device
Resmed (RMD) Achieves FDA Clearance for Smart Comfort Device
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has rece...
Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed
(RTTNews) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD)
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD)
Should You Continue to Hold RMD Stock in Your Portfolio?
Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD)
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD)
ResMed (RMD) Dropped from Goldman Sachs' APAC Conviction List
ResMed (RMD) Dropped from Goldman Sachs' APAC Conviction List
PETER FARRELL At ResMed Acquires Stock Options Worth $7K
A substantial insider move unfolded on November 26, as FARRELL, Board Member at ResMed (NYSE: RMD), reported the acquisition of stock options for 1,331 shares in an SEC filing. What Happened: Disclos...
Michael J Farrell Makes Strategic Play: Invests $179K In ResMed Stock Options
Michael J Farrell , Chairman and CEO at ResMed (NYSE: RMD), reported acquisition of company stock options on November 26, according to a new SEC filing. What Happened: Revealed in a Form 4 filing on ...
Insider Sell: Witte De Sells 2,055 Shares of ResMed Inc (RMD)
Insider Sell: Witte De Sells 2,055 Shares of ResMed Inc (RMD)
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may b...
ResMed Inc. (RMD) Announces Key Amendments to Incentive and Stock Purchase Plans
ResMed Inc. (RMD) Announces Key Amendments to Incentive and Stock Purchase Plans
Peter C Farrell Exercises Options, Realizes $1.65M
A substantial insider activity was disclosed on November 18, as Farrell, Board Member at ResMed (NYSE: RMD), reported the exercise of a large sell of company stock options. What Happened: A Form 4 fi...
Noteworthy Tuesday Option Activity: AAPL, NVDA, RMD
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Apple Inc (Symbol: AAPL), where a total of 396,023 contracts have traded so far, representing ap...
ResMed: Safe Bet For A Recession Environment
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
Ex-Dividend Reminder: UNITIL, American Water Works and ResMed
Looking at the universe of stocks we cover at Dividend Channel, on 11/13/25, UNITIL Corp (Symbol: UTL), American Water Works Co, Inc. (Symbol: AWK), and ResMed Inc. (Symbol: RMD) will all trade ex-div...
RMD: Baird Lowers Price Target for ResMed to $300 While Maintaining Outperform Rating | RMD ...
RMD: Baird Lowers Price Target for ResMed to $300 While Maintaining Outperform Rating | RMD Stock News
RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News
RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News
Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD Stock News
Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD Stock News
Mizuho Maintains 'Outperform' for RMD but Lowers Price Target | RMD Stock News
Mizuho Maintains 'Outperform' for RMD but Lowers Price Target | RMD Stock News
These Analysts Revise Their Forecasts On ResMed Following Q1 Results
ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday.